The Latest Cardiac and Vascular News
MARLBOROUGH, Mass., March 13, 2019 /PRNewswire/ — Boston Scientific Corporation (NYSE: BSX) announced it has received CE Mark and initiated a limited market release of the next generation WATCHMAN FLX™ Left Atrial Appendage Closure (LAAC) Device in Europe. Patients with AF are five times more likely to suffer a stroke than someone with a normal heart […]
MARLBOROUGH, Mass., March 11, 2019 /PRNewswire/ — Boston Scientific Corporation (NYSE: BSX) today announced key data that will be featured at EHRA 2019, the annual congress of the European Heart Rhythm Association (EHRA) in Lisbon, Portugal, on March 17-19. Two late-breaking clinical trials will be presented, including: Outcomes from AF-FICIENT I, a prospective, multicenter, single arm […]
MARLBOROUGH, Mass., Feb. 25, 2019 /PRNewswire/ — Boston Scientific Corporation (NYSE: BSX) completed a public offering of $4.3 billion aggregate principal amount of its senior notes. The public offering consists of $850 million of 3.450% notes due 2024, $850 million of 3.750% notes due 2026, $850 million of 4.000% notes due 2029, $750 millionof 4.550% notes due 2039 and $1.0 billion of 4.700% notes due […]
MARLBOROUGH, Mass., Feb. 6, 2019 /PRNewswire/ — Boston Scientific Corporation (NYSE: BSX) generated sales of $2.561 billion during the fourth quarter of 2018. This represents growth of 6.3 percent on a reported basis, 8.2 percent on an operational1 basis and 7.0 percent on an organic2 basis, all compared to the prior year period. The company reported […]
LEIPZIG, Germany and MARLBOROUGH, Mass., Jan. 22, 2019 /PRNewswire/ — Today, Boston Scientific (NYSE: BSX) announced positive 12-month data demonstrating that patients who were treated with the VICI VENOUS STENT® System for iliac and femoral vein obstructions exhibited a high rate of patent, or open, target lesions. Primary safety and efficacy results from the VIRTUS trial […]
MARLBOROUGH, Mass. and IRVINE, Calif., Jan. 15, 2019 /PRNewswire/ — Boston Scientific Corporation (NYSE: BSX) and Edwards Lifesciences Corporation (NYSE: EW) today announced that the companies have reached an agreement to settle all outstanding patent disputes between the companies in all venues around the world. All pending cases or appeals in courts and patent offices between […]
MARLBOROUGH, Mass., Jan. 8, 2019 /PRNewswire/ — Boston Scientific Corporation (NYSE: BSX) generated sales, based upon preliminary unaudited financial information, of approximately $2.56 billion during the fourth quarter of 2018. This represents growth of approximately 6.3 percent on a reported basis, approximately 8.2 percent on an operational1 basis and approximately 7.0 percent on an organic2 basis, […]
MARLBOROUGH, Mass., Dec. 27, 2018 /PRNewswire/ — Boston Scientific Corporation (NYSE: BSX) today announced it exercised its option to acquire the remaining shares of Millipede, Inc, a privately-held company in Santa Rosa, Calif., upon its recent successful completion of a first-in-human clinical study. The acquisition will expand the Boston Scientific Structural Heart portfolio to include […]
MARLBOROUGH, Mass., Dec. 11, 2018 /PRNewswire/ — Boston Scientific Corporation (NYSE: BSX) today announced that a jury in the United States (U.S.) District Court for the District of Delaware determined that the Boston Scientific U.S. patent 8,992,608 is valid and that Edwards Lifesciences’ Sapien 3™ Aortic Valve infringes this patent and that Edwards owes Boston Scientific infringement damages […]
IRVINE, Calif., Dec. 11, 2018 /PRNewswire/ — Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, commented today on a federal jury’s decisions in patent litigation between Edwards and Boston Scientific: The jury awarded $35 million in damages to Boston Scientific for infringement of U.S. […]
